Abstract
Granulomatous diseases in childhood present a complex diagnostic landscape, particularly when histological and clinical findings overlap with those of systemic inflammatory or histiocytic disorders. A subset of these conditions may represent the clinical onset of inborn errors of immunity (IEI), such as Mendelian Susceptibility to Mycobacterial Disease (MSMD), where atypical or sterile granulomas may obscure the underlying infectious or genetic etiology. Recognition of IEI behind granulomatous diseases can radically alter patient’s prognosis and therapeutic management. This report describes the case of a 11-years-old with an initial diagnosis of Rosai-Dorfman disease based on clinical and and histological findings. Following relapse after steroid tapering the diagnosis was revised to sarcoidosis, supported by non-caseating granulomas and compatible laboratory findings. Only after cultures from biopsy specimens revealed Mycobacterium avium complex (MAC), immunological investigations were undertaken, revealing a STAT1 dominant negative deficiency, consistent with MSMD. This report underscores the need of considering IEI in pediatric patients presenting with granulomatous inflammation, especially when clinical course is atypical or refractory to standard immunosuppressive therapies. Early microbiological and immunogenetic assessment is essential to avoid diagnostic delay, prevent inappropriate treatment, and guide targeted antimicrobial therapy.
Introduction
Granulomatous diseases encompass a wide range of conditions defined by the formation of inflammatory infiltrates of macrophages, epithelioid cells, and multinucleated giant cells, surrounded by fibroblasts and lymphocytes. The differential diagnosis of granulomatous diseases in children is particularly challenging, as granulomas can form in response to a broad spectrum of triggers, such as infectious agents, as well as non-infectious causes, including malignancies, inborn errors of immunity (IEI), rare histiocytic disorders such as Rosai-Dorfman disease – characterized by infiltration of lymph nodes or extra-nodal tissues by non-malignant histiocytes – and systemic inflammatory disorders (1, 2). Among these, sarcoidosis poses a particular diagnostic challenge, due to its nonspecific clinical presentations, lack of pathognomonic signs, and the absence of reliable laboratory tests (3–5). Sarcoidosis is a chronic multisystem inflammatory disease which can potentially affect various organs, including the skin, lungs, kidneys, bones, reticuloendothelial and central nervous system (6, 7). While it is more commonly seen in adults, pediatric cases are rare, with an estimated incidence of 0.22-0.29 per 100,000 children (8, 9). The diagnosis of sarcoidosis is further complicated by the fact that sarcoid-like lesions can also result from infections, such as mycobacteria, which are more commonly encountered in pediatric patients. This is particularly difficult in those with underlying IEI, such as Mendelian Susceptibilities to Mycobacterial Diseases (MSMD), where typical histological features of mycobacterial infection may be absent.
MSMD are IEI affecting the interaction between mononuclear phagocytes and T-helper cells just as their response to interleukin-12/interferon-gamma (IL12/IFNγ) (10). This leads to susceptibility to intracellular pathogens like mycobacteria, but also infections by fungi, Salmonella spp, Burkholderia spp, Listeria spp, and herpes viruses. Since the first report of familial disseminated atypical mycobacteriosis in 1964 (11), interest in MSMD has gained momentum, driven by advances in genetic research and laboratory diagnostics. As of 2022, 17 single-gene defects have been identified within the MSMD subgroup (12), though genetic causes remain unknown in nearly 50% of cases (13).
Among the known MSMD genes, signal transducer and activator of transcription 1 (STAT1) encodes a protein composed of four domains, that upon IFNγ stimulation, undergoes phosphorylation at Tyr701, homodimerization and translocation to the nucleus, playing a critical role in the defense against various pathogens, primarily mycobacteria (14).
STAT1 deficiencies can be autosomal recessive (AR) or autosomal dominant (AD). AR STAT1 deficiencies may be hypomorphic (partial), leading to milder MSMD forms, or amorphic (complete), which often results in death during infancy due to disseminated Bacillus Calmette-Guerin (BCG) or viral infections unless treated with hematopoietic stem cell transplantation (HSCT) (15). Conversely, AD STAT1 deficiencies generally cause less severe infections in childhood, as they exert a milder effect on the IFNα/β signaling pathway, with BCGitis, multifocal osteomyelitis and Mycobacterium avium complex (MAC) infections representing the most common clinical manifestations, as demonstrated by a recent comprehensive review, which analyzed 24 cases of AD STAT1 deficiencies (16).
We report a case of a previously healthy female who, due to the nonspecific clinical and histological features, was initially misdiagnosed with histiocytosis, later with sarcoidosis, and ultimately found to harbor AD STAT1 deficiency following the pivotal microbiological identification of MAC from one of her lesions.
Case presentation
The patient is a female and first child of a healthy, non-consanguineous Italian family. Her past clinical history was notable for two episodes of viral pneumonia, without complications, and for the onset of multiple follicular papules at the age of 7 years, which first involved the knees and then spread to the trunk and face, gradually worsening over time (Figure 1a). Histopathological analysis of an initial skin biopsy demonstrated very subtle and nonspecific alterations, characterized by minimal spongiosis and few mixed perivascular inflammatory infiltrates (Figures 1b, c). However, a second biopsy at the age of 11 years, following the emergence of erythematous plaques on the trunk (Figure 1d), revealed a dense BRAF600E-negative lymphoplasmacytic inflammatory infiltrate with histiocytic-macrophagic S100-positive cells and emperipolesis (Figures 1e-g). These histological findings raised the possibility of Rosai-Dorfman disease.
Figure 1
A whole-body magnetic resonance imaging (WB-MRI) for staging (Figure 2a) showed multiple hyperintense lesions in long bones and skull, and lymph node enlargements, particularly in cervical region. Thus, the patient was started on oral steroids (prednisone 1 mg/kg/day), then tapered over six weeks, with clinical improvement. Follow-up WB-MRIs showed progressive partial regression of bone lesions and an overall reduction of lymph node size. After discontinuation of treatment, the patient remained asymptomatic for nine months, at which point disease relapsed with new skin flare, multiple lymph node and bone lesions, and brain involvement confirmed on MRI spectroscopy (Figure 2b), although the patient remained neurologically asymptomatic. Oligoclonal bands, Link index, and autoantibodies (anti-myelin oligodendrocyte glycoprotein, and anti-aquaporin4) on cerebrospinal fluid were found to be normal.
Figure 2
The partial response to steroid therapy, combined with the atypical clinical presentation, prompted a reconsideration of the initial presumptive diagnosis of Rosai-Dorfman disease. Thus, for histological redefinition and molecular deepening, the patient underwent a lymph node biopsy, revealing multiple non-necrotizing epithelioid granulomas, with multinucleated S100+ macrophages and emperipolesis. Although the findings were not definitively diagnostic, they were highly suggestive of sarcoidosis (Figures 1h, i). This diagnosis was then confirmed by Expert review at the European reference center for rare histiocytoses. Laboratory results supported the latter histological findings. showed nonspecific pulmonary lesions.
Despite the absence of significant pulmonary involvement on high resolution computed tomography or lung functionality, the patient was treated as for sarcoidosis with a new course of oral steroids (prednisone 1 mg/kg/day), leading to marked improvement in skin lesions and cervical lymph node size.
As the initial findings did not suggest an infectious etiology, microbiological cultures were not initially performed. However, given disease progression, these were later conducted on the biopsy specimen, revealing Mycobacterium avium complex (MAC). Thus, the patient started triple oral antimycobacterial therapy including clarithromycin (15 mg/kg/day), ethambutol (15 mg/kg/day), and moxifloxacin (8 mg/kg/day) then replaced with rifampicin (15 mg/kg/day) after 4 weeks to minimize potential side effects of fluoroquinolones. No side effects were reported.
In the suspicion of an underlying IEI, an extensive immunological work-up was performed (Supplementary Table S1), which revealed absent STAT1 phosphorylation after IFNγ stimulation (Supplementary Figure A), confirmed during steroid tapering.
Targeted next-generation sequencing identified two STAT1 variants. The first (c.1823G>A, p.R608Q) was a known pathogenic dominant-negative loss-of-function (LOF) variant previously reported in MSMD (17). The second (c.129-9A>G) was a variant of unknown significance (VUS), initially considered potentially pathogenic due to its rarity and location at a splicing site, but later reconsidered as this one was also found in the healthy mother. Clinical exome sequencing excluded pathogenic variants or VUS in genes linked to histiocytic disorders and granulomatous autoinflammatory diseases, including Blau syndrome.
Four months after starting antibiotics and during steroid tapering, mild skin lesions persisted without evident improvement (Figure 1j); however, WB-MRI showed overall improvement (Figure 2c), and no systemic signs of disease activity were observed. Consequently, alternative therapeutic options, such as IFNγ, were considered but not administered, given the favorable radiological response. Moxifloxacin was reintroduced to enhance CNS penetration and strengthen MAC treatment, while steroid therapy was discontinued. The patient remained asymptomatic and did not experience any new relapse following steroid discontinuation. Follow-up brain MRIs, conducted every three months, showed progressive regression of all previously identified lesions (Figure 2d). Moxifloxacin was stopped after 9 months, and triple therapy after 13 months, followed by ongoing azithromycin prophylaxis. After 18 months, the patient remains in excellent clinical conditions with no infections reported. Azithromycin prophylaxis is planned to continue for an extended period to prevent relapse, with close clinical, laboratory and radiological monitoring. The long-term prognosis remains cautiously optimistic given the patient’s favorable response to therapy so far.
A chronological overview of the patient’s clinical progression is represented in Figure 3.
Figure 3
Discussion
Pediatric granulomatous disorders pose a significant diagnostic challenge because of their rarity, lack of pathognomonic features, and overlapping clinical presentations. In these circumstances, pediatricians should consider IEI as a possible underlying cause, especially when granulomas are sterile or display atypical features.
Granulomas are reported in approximately 1–4% of IEI (18) and can be either infectious or sterile in origin. In disorders such as common variable immunodeficiency (CVID), combined immunodeficiency (CID), autoinflammatory disorders (19) and sometimes chronic granulomatous disease (CGD) (20), granulomas often result from sterile hyperinflammatory response. On the contrary, in conditions like MSMD, defective immune responses lead to chronic infections by tuberculous and non-tuberculous mycobacteria (19), fungi (21), or viruses (22).
One of the key diagnostic difficulties lies in the fact that granulomas observed in these immune defects, whether infectious or sterile, may closely mimic those seen in other granulomatous disorders. For example, sarcoid-like lesions have been reported in CID due to RAG1/2 mutations, whereas PRKCD deficiency has been associated with non-Langerhans histiocytosis (23). Syndromic CID, such as ataxia-telangiectasia or cartilage-hair hypoplasia, may also present with sarcoid-like lesions or histiocytic infiltrates (23).
This diagnostic overlap could result in microbial cultures of histological specimens not being systematically pursued in routine clinical practice.
A key strength of this report is the clear retrospective distinction between the final diagnosis of MSMD and other granulomatous conditions like Rosai-Dorfman disease or sarcoidosis.
Our patient initially presented with complex clinical and histological features suggestive of Rosai-Dorfman disease, supported by typical cervical lymph node and long bone involvement (24). Later, disease flare after steroid withdrawal and central nervous system involvement prompted diagnostic reassessment, with sarcoidosis considered in light of new supportive histological and laboratory findings. However, the presentation was atypical, characterized by prominent skeletal involvement (25) and the absence of clear pulmonary (26), articular, and ocular manifestations (27).
The patient’s therapeutic course provided further insight. Initial steroid therapy achieved transient disease control, as expected firstly in Rosai-Dorfman disease then in sarcoidosis. However, closer evaluation suggests this response may have reflected the steroids’ ability to modulate granulomatous inflammation, a known effect in mycobacterial infections (28, 29). Although we cannot definitively ascertain if MAC was present in all granulomas, the progressive resolution of the lesions with antimycobacterial therapy alone suggests that the disease was not purely inflammatory, as initially suspected. Whether it was disseminated mycobacterial disease or an inflammatory response triggered by MAC, in either case, the elimination of the infection led to clinical resolution. This observation is critical, as a pure sarcoidosis would not have improved, but even worsened, following steroid discontinuation.
This clinical course underscores a diagnostic consideration: granulomatous diseases that don’t show sustained improvement with immunosuppression should prompt deep investigation for underlying infections or immune deficiencies.
This is particularly relevant in IEI such as MSMD, which selectively affect innate immunity, where infectious history or laboratory assessments often lack suggestive hallmarks for immunodeficiency. Notably, delayed complications following BCG vaccination—often among the earliest clinical features of MSMD—may go undocumented, as in our patient, due to the absence of routine BCG immunization in countries like Italy.
These diagnostic ambiguities raise broader questions about the interplay between granulomatous inflammation, infectious triggers, and immunity, particularly in conditions like sarcoidosis, whose etiology remains poorly understood. IFNγ signaling, essential for the immune response to mycobacteria, also appears to play a key pathogenic role across multiple granulomatous disorders. This is supported by a recent case describing a patient with a milder form of Blau syndrome – a monogenic granulomatous disease - due to the interference of a coexisting dominant-negative IFNGR1 mutation (30).
The relationship between sarcoidosis, mycobacterial infections, and immune dysregulation has been debated for decades (31, 32). This association dates back to 1960, when Mycobacterium tuberculosis was first reported in multiple patients with sarcoidosis (33). More recently, NTM have been detected in patients meeting clinical and histopathological criteria for sarcoidosis in many reports in the literature (34–38). Notably, when the histology was described, necrosis was not present in the granulomas. In most cases however, genetic investigations to rule out an underlying IEI were not conducted.
NTM infections are often associated with non-necrotizing granulomas, particularly in individuals immunocompromised by Human Immunodeficiency Virus (HIV) or immunosuppressive drugs, where histological findings may be nonspecific (39). In our case, MAC was isolated from a non-caseating granuloma (Figure 4), initially interpreted as consistent with sarcoidosis, prompting further immunological assessment that ultimately led to the diagnosis of MSMD. Thus, it could be speculated that some sarcoidosis diagnoses, based on clinical, laboratory and histological criteria may hide unidentified mycobacterial infections or genetically defined IEI. In 2022, in effect, sarcoid-like lesions were described in a 31-year-old woman with disseminated Mycobacterium genavense infection then found to be due to IL12Rβ1 deficiency (40). Retrospectively, and in light of our case, it cannot be ruled out that other cases previously described in the literature may have hidden unrecognized MSMD.
Figure 4
The absence of necrotic areas in granulomas has been supported by STAT1-knockout mouse models (41). Similarly, cases of patients with dominant negative STAT1 LOF mutations also document non-necrotic granulomas in the context of mycobacterial infections (16, 42). However, this is not universal, as residual STAT1 function in some cases may allow necrosis to form, emphasizing the heterogeneity of clinical presentations (43, 44).
In pediatric patients with sarcoidosis or other granulomatous manifestations, certain “red flags” should prompt a thorough immunological evaluation, including functional and genetic testing. These include early onset of symptoms, particularly in childhood, but also atypical multisystem involvement, such as hepatic and bone marrow infiltration, or absent lung involvement; poor response to conventional therapies, such as steroids; a family history of immunodeficiency; history of recurrent infections; and the isolation of pathogens, especially if atypical mycobacteria. Microbiological cultures of biopsy specimens, thus, should be prioritized as a standard diagnostic step before proceeding to advanced diagnostic or therapeutic interventions. These steps have significant prognostic and therapeutic relevance, as empirical immunosuppression may aggravate unrecognized latent infections. Our case, indeed, illustrates how pathogen identification within sarcoid-like lesions can shift the diagnostic and therapeutic approach, with a profound impact on both the clinical course and the patient’s quality of life.
This report also underscores the need of a multidisciplinary approach involving also immunologists, rheumatologists, onco-hematologists, and pathologists to improve diagnostic accuracy, optimize management, and advance understanding of the relationship between IEI and granulomatous diseases in pediatric patients.
Statements
Data availability statement
The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Ethics statement
Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article. Written informed consent was obtained from the participant/patient(s) for the publication of this case report.
Author contributions
WS: Writing – original draft, Visualization, Methodology, Investigation, Writing – review & editing, Data curation, Conceptualization. FQ: Methodology, Writing – review & editing, Data curation, Writing – original draft. CC: Writing – original draft, Writing – review & editing, Validation, Supervision. LL: Writing – review & editing, Writing – original draft, Supervision, Validation. LP: Writing – review & editing, Writing – original draft, Methodology, Data curation. AB: Validation, Supervision, Writing – review & editing, Writing – original draft. TO: Writing – review & editing, Validation, Supervision, Writing – original draft. ES: Writing – original draft, Validation, Supervision, Writing – review & editing. GS: Supervision, Validation, Writing – review & editing, Writing – original draft. LB: Validation, Supervision, Writing – review & editing, Writing – original draft. EV: Supervision, Writing – review & editing, Writing – original draft, Validation. LG: Validation, Writing – original draft, Supervision, Writing – review & editing. CA: Supervision, Writing – review & editing, Writing – original draft, Validation. SR: Validation, Conceptualization, Supervision, Writing – review & editing, Methodology, Writing – original draft, Visualization.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported in part by funds from the ‘Current Research Annual Funding’ of the Italian Ministry of Health.
Acknowledgments
We would like to thank the patient for giving us permission to publish her case and the hospital personnel who was involved in the diagnostic workup and treatment.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2025.1634661/full#supplementary-material
References
1
RoseCDNevenBWoutersC. Granulomatous inflammation: The overlap of immune deficiency and inflammation. Best Pract Res Clin Rheumatol. (2014) 28:191–212. doi: 10.1016/j.berh.2014.03.006
2
AblaOJacobsenEPicarsicJKrenovaZJaffeREmileJFet al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. (2018) 131:2877–90. doi: 10.1182/blood-2018-03-839753
3
DrentMCrouserEDGrunewaldJ. Challenges of sarcoidosis and its management. New Engl J Med. (2021) 385:1018–32. doi: 10.1056/NEJMra2101555
4
HeinleRChangC. Diagnostic criteria for sarcoidosis. Autoimmun Rev. (2014) 13:383–7. doi: 10.1016/j.autrev.2014.01.035
5
ValeyreDBernaudinJFUzunhanYKambouchnerMBrilletPYSoussanMet al. Clinical presentation of sarcoidosis and diagnostic work-up. Semin Respir Crit Care Med. (2014) 35:336–51. doi: 10.1055/s-0034-1381229
6
ValeyreDPrasseANunesHUzunhanYBrilletPYMüller-QuernheimJ. Sarcoidosis. Lancet. (2014) 383:1155–67. doi: 10.1016/S0140-6736(13)60680-7
7
SpagnoloP. Sarcoidosis: a critical review of history and milestones. Clin Rev Allergy Immunol. (2015) 49:1–5. doi: 10.1007/s12016-015-8480-0
8
GedaliaAKhanTAShettyAKDimitriadesVREspinozaLR. Childhood sarcoidosis: Louisiana experience. Clin Rheumatol. (2016) 35:1879–84. doi: 10.1007/s10067-015-2870-9
9
HoffmannAMilmanNBygKE. Childhood sarcoidosis in Denmark 1979–1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. (2004) 93:30–6. doi: 10.1111/j.1651-2227.2004.tb00670.x
10
CasanovaJL. Mendelian susceptibility to mycobacterial infection in man. Swiss Med Wkly. (2001) 131:445–54. doi: 10.4414/smw.2001.09763
11
EngbaekHC. Three cases in the same family of fatal infection with M. avium. Acta Tuberc Pneumol Scand. (1964) 45:105–17.
12
TangyeSGAl-HerzWBousfihaACunningham-RundlesCFrancoJLHollandSMet al. Human inborn errors of immunity: 2022 update on the classification from the international union of immunological societies expert committee. J Clin Immunol. (2022) 42:1473–507. doi: 10.1007/s10875-022-01289-3
13
Al-MuhsenSCasanovaJL. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J Allergy Clin Immunol. (2008) 122:1043–51; quiz 1052–3. doi: 10.1016/j.jaci.2008.10.037
14
StarkGRKerrIMWilliamsBRSilvermanRHSchreiberRD. How cells respond to interferons. Annu Rev Biochem. (1998) 67:227–64. doi: 10.1146/annurev.biochem.67.1.227
15
DupuisSDargemontCFieschiCThomassinNRosenzweigSHarrisJet al. Impairment of mycobacterial but not viral immunity by a germline human STAT1 mutation. Science. (2001) 293:300–3. doi: 10.1126/science.1061154
16
TsumuraMMikiMMizoguchiYHirataONishimuraSTamauraMet al. Enhanced osteoclastogenesis in patients with MSMD due to impaired response to IFN-γ. J Allergy Clin Immunol. (2022) 149:252–261.e6. doi: 10.1016/j.jaci.2021.05.018
17
ZengYYingWWangWHouJLiuLSunBet al. Clinical and genetic characteristics of BCG disease in Chinese children: a retrospective study. J Clin Immunol. (2023) 43:756–68. doi: 10.1007/s10875-022-01422-2
18
LeungJSullivanKEPerelyginaLIcenogleJPFuleihanRLLanzieriTM. Prevalence of granulomas in patients with primary immunodeficiency disorders, United States: data from national health care claims and the US immunodeficiency network registry. J Clin Immunol. (2018) 38:717–26. doi: 10.1007/s10875-018-0534-7
19
BousfihaAAJeddaneLMoundirAPoliMCAksentijevichICunningham-RundlesCet al. The 2024 update of IUIS phenotypic classification of human inborn errors of immunity. J Hum Immun. (2025) 1:e20250002. doi: 10.70962/jhi.20250002
20
HillHR. Hyperinflammatory pulmonary disease in chronic granulomatous disease. Pediatr Infect Dis J. (2011) 30:808. doi: 10.1097/INF.0b013e31822835ba
21
HsuAPKorzeniowskaAAguilarCCGuJKarlinsEOlerAJet al. Immunogenetics associated with severe coccidioidomycosis. JCI Insight. (2022) 7:e159491. doi: 10.1172/jci.insight.159491
22
NotarangeloLD. Rubella virus–associated granulomas in immunocompetent adults—Possible implications. JAMA Dermatol. (2022) 158:611–3. doi: 10.1001/jamadermatol.2022.0055
23
SaccoKAGazzinANotarangeloLDDelmonteOM. Granulomatous inflammation in inborn errors of immunity. Front Pediatr. (2023) 11:1110115/full. doi: 10.3389/fped.2023.1110115/full
24
RavindranARechKL. How I diagnose Rosai-Dorfman disease. Am J Clin Pathol. (2023) 160:1–10. doi: 10.1093/ajcp/aqad047
25
KendigEL. The clinical picture of sarcoidosis in children. Pediatrics. (1974) 54:289–92. doi: 10.1542/peds.54.3.289
26
HunninghakeGWCostabelUAndoMBaughmanRCordierJFdu BoisRet al. ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis. (1999) 16:149–73. doi: 10.1164/ajrccm.160.2.ats4-99
27
HoffmannALMilmanNBygKE. Childhood sarcoidosis in Denmark 1979-1994: incidence, clinical features and laboratory results at presentation in 48 children. Acta Paediatr. (2004) 93:30–6. doi: 10.1111/j.1651-2227.2004.tb00670.x
28
DolecekR. Certain steroids in the treatment of pulmonary tuberculosis. Cas Lek Cesk. (1951) 90:1160–3.
29
CritchleyJAYoungFOrtonLGarnerP. Corticosteroids for prevention of mortality in people with tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. (2013) 13:223–37. doi: 10.1016/S1473-3099(12)70321-3
30
ParackovaZBloomfieldMVrabcovaPZentsovaIKlocperkAMilotaTet al. Mutual alteration of NOD2-associated Blau syndrome and IFNγR1 deficiency. J Clin Immunol. (2020) 40:165–78. doi: 10.1007/s10875-019-00720-6
31
GuptaDAgarwalRAggarwalANJindalSK. Molecular evidence for the role of mycobacteria in sarcoidosis: a meta-analysis. Eur Respir J. (2007) 30:508–16. doi: 10.1183/09031936.00002607
32
FangCHuangHXuZ. Immunological evidence for the role of mycobacteria in sarcoidosis: A meta-analysis. PloS One. (2016) 11:e0154716. doi: 10.1371/journal.pone.0154716
33
ScaddingJG. Mycobacterium tuberculosis in the aetiology of sarcoidosis. Br Med J. (1960) 2:1617–23. doi: 10.1136/bmj.2.5213.1617
34
GanatraSSharmaAD’AgostinoRGageTKinnunenP. Mycobacterium chimaera mimicking sarcoidosis. Methodist Debakey Cardiovasc J. (2018) 14:301–2. doi: 10.14797/mdcj-14-4-301
35
GriceK. Sarcoidosis and Mycobacterium avium-intracellulare cutaneous abscesses. Clin Exp Dermatol. (1983) 8:323–7. doi: 10.1111/j.1365-2230.1983.tb01787.x
36
el-ZaatariFANaserSAMarkesichDCKalterDCEngstandLGrahamDY. Identification of Mycobacterium avium complex in sarcoidosis. J Clin Microbiol. (1996) 34:2240–5. doi: 10.1128/jcm.34.9.2240-2245.1996
37
SatoYTamuraKSeitaM. Multiple osteomyelitis due to Mycobacterium avium with no pulmonary presentation in a patient of sarcoidosis. Intern Med. (1992) 31:489–92. doi: 10.2169/internalmedicine.31.489
38
EppsREel-AzharyRAHellingerWCWinkelmannRKVan ScoyRE. Disseminated cutaneous Mycobacterium avium-intracellulare resembling sarcoidosis. J Am Acad Dermatol. (1995) 33:528–31. doi: 10.1016/0190-9622(95)91407-2
39
PenningtonKMVuAChallenerDRiveraCGShwetaFNUZeuliJDet al. Approach to the diagnosis and treatment of non-tuberculous mycobacterial disease. J Clin Tuberc Other Mycobact Dis. (2021) 24:100244. doi: 10.1016/j.jctube.2021.100244
40
DenicolòSLaydevantSFinkJGeigerCPizziniASarclettiMet al. Sarcoid-like lesions obfuscating the diagnosis of disseminated Mycobacterium genavense infection in a patient with IL-12Rβ1-associated immunodeficiency. BMC Infect Dis. (2022) 22:770. doi: 10.1186/s12879-022-07644-4
41
AlySMagesJReilingNKalinkeUDeckerTLangRet al. Mycobacteria-induced granuloma necrosis depends on IRF-1. J Cell Mol Med. (2009) 13:2069–82. doi: 10.1111/j.1582-4934.2008.00470.x
42
KagawaRFujikiRTsumuraMSakataSNishimuraSItanYet al. Alanine-scanning mutagenesis of human STAT1 to estimate loss- or gain-of-function variants. J Allergy Clin Immunol. (2017) 140:232–41. doi: 10.1016/j.jaci.2016.09.035
43
DolezalovaKStrachanTMatejRRicnaDBloomfieldM. Manifestations of cutaneous mycobacterial infections in patients with inborn errors of IL-12/IL-23-IFNγ immunity. Eur J Dermatol. (2022) 32:495–504. doi: 10.1684/ejd.2022.4281
44
Le VoyerTSakataSTsumuraMKhanTEsteve-SoleAAl-SaudBKet al. Genetic, immunological, and clinical features of 32 patients with autosomal recessive STAT1 deficiency. J Immunol. (2021) 207:133–52. doi: 10.4049/jimmunol.2001451
Summary
Keywords
Mendelian susceptibility to mycobacterial diseases, innate immunity, STAT1, sarcoidosis, mycobacterium avium complex Mendelian susceptibility to mycobacterial diseases (MSMD), mycobacterium avium complex (MAC), nontuberculous mycobacteria (NTM), interferon-gamma (IFNg)
Citation
Sarli WM, Quaranta F, Canessa C, Lodi L, Pisano L, Buccoliero AM, Oranges T, Sieni E, Simonini G, Bartolini L, Venturini E, Galli L, Azzari C and Ricci S (2025) Uncovering hidden immune defects in childhood granulomatous disorders: a case report. Front. Immunol. 16:1634661. doi: 10.3389/fimmu.2025.1634661
Received
24 May 2025
Accepted
30 June 2025
Published
18 July 2025
Volume
16 - 2025
Edited by
Hirokazu Kanegane, Tokyo Medical and Dental University, Japan
Reviewed by
Karolína Doležalová, Thomayer University Hospital, Czechia
Cecilia Buján Bonino, Complejo Hospitalario Universitario de Santiago, Spain
Updates
Copyright
© 2025 Sarli, Quaranta, Canessa, Lodi, Pisano, Buccoliero, Oranges, Sieni, Simonini, Bartolini, Venturini, Galli, Azzari and Ricci.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Francesca Quaranta, francesca.quaranta@meyer.it
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.